Ennovate Pharma is an early-stage biotech company specializing in developing novel personalized therapies for autoimmune and inflammatory diseases.

Ennovate Pharma is developing breakthrough therapeutics addressing refractory and non-responder patients of current cytokine-based standard of care treatments by harnessing the power of innate immunity in autoimmune and inflammatory diseases.

Co-founded by Enable Medicine and General Inception, Ennovate Pharma combines standard of care data with cutting-edge single cell spatial biology data to develop therapeutic antibodies quickly and efficiently. We’re integrating high parameter data to discover novel insights using our proprietary AI/ML algorithms. Our focus is to analyze multiple indications to identify therapeutically tractable cell types and targets.

We are addressing refractory and non-responder populations in autoimmune diseases. Our initial pipeline comprises three lead programs targeting a key inflammatory cytokine junction (ENNO-001), eosinophils and mast cells (ENNO-002), and innate immunity (ENNO-003) with next-generation monovalent and bifunctional/bispecific biologics.